Propel Bio Partners
Propel Bio Partners is a private equity investment firm established in March 2022 and headquartered in Los Angeles, California. Founded by Dr. Leen Kawas and Richard Kayne, the firm focuses on investing in high-potential companies within the biosciences sector, particularly those with disruptive technologies that are ready for clinical trials or regulatory approval. Propel Bio Partners aims to provide both capital and strategic guidance to its portfolio companies. Dr. Kawas, who has extensive experience in drug discovery and clinical trials from her previous role as Co-Founder and CEO of a pharmaceutical company, leads the firm alongside Richard Kayne, a veteran in private equity and venture capital. They are joined by Dr. Dasom Yoo, a Senior Advisor with expertise in regenerative medicine. The firm’s advisory board consists of leaders from prominent biosciences companies and government agencies, ensuring that their investments benefit from specialized knowledge in research, medicine, and business.
Top Stages
4 past transactions
Achieve Life Sciences
Post in 2024
Achieve Life Sciences Inc., headquartered in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on developing and commercializing cytisine, a plant-based alkaloid, as a smoking cessation aid. Cytisine interacts with nicotine receptors in the brain to help reduce withdrawal symptoms associated with quitting smoking. The company has license agreements with Sopharma AD and University of Bristol for this purpose. Achieve Life Sciences aims to address the global smoking health epidemic by advancing cytisine as a widely available treatment option.
Inherent Biosciences
Series A in 2022
Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.
Persephone Biosciences
Seed Round in 2022
Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.
OmniVis
Seed Round in 2021
OmniVis is a biotechnology company that has developed a portable pathogen detection platform aimed at improving the speed, accuracy, and affordability of pathogen testing. Its ultrasensitive handheld device provides a cost-effective alternative to traditional laboratory testing by delivering accurate results in under 30 minutes directly at the source. The platform is designed to analyze swabs or liquid samples, enabling health organizations to detect various pathogens efficiently. By utilizing single-use disposable test kits in conjunction with its handheld hardware, OmniVis allows for rapid and reliable pathogen measurement, significantly reducing the time to detection while remaining user-friendly and accessible.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.